Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lung Neoplasms 1Hot Flashes 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Vincristine 7Cyclophosphamide 710-propargyl-10-deazaaminopterin 7Prednisone 6Doxorubicin 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5romidepsin 3belinostat 3Gemcitabine 3liposomal doxorubicin 2duvelisib 1Vitamin B 12 1MLN 8237 1Folic Acid 1Etoposide 1E7777 fusion protein 1Decitabine 1CHOP protocol 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1BAEC protocol 1Alemtuzumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Peripheral × Folic Acid × Clear all
NCT03349333 2019-10-01

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Completed
85 enrolled 26 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡